Frailty metabolomic signature

Frailty metabolomic signature mediates mortality in humans (up to 35%).

“Mediation analyses indicated that the metabolomic signatures statistically explained up to 35% of the observed frailty-mortality association.”

Humansmediation analysis

Frailty-related plasma metabolomic signatures predict long-term mortality risk and implicate systemic aging pathways: evidence from a prospective cohort study

npj aging·13 Jan 2026

Frailty metabolomic signature decreases life expectancy in humans (4.1 fewer years).

“At age 60, individuals above the median signature level were estimated to have 4.1 fewer years of life expectancy.”

Humans

Frailty-related plasma metabolomic signatures predict long-term mortality risk and implicate systemic aging pathways: evidence from a prospective cohort study

npj aging·13 Jan 2026

Frailty metabolomic signature raises the risk of cardiovascular mortality in humans (>2.5-fold).

“Individuals in the highest-risk tertile had more than 2.5-fold higher risks of cardiovascular, respiratory, and digestive mortality.”

Humanshighest-risk tertile

Frailty-related plasma metabolomic signatures predict long-term mortality risk and implicate systemic aging pathways: evidence from a prospective cohort study

npj aging·13 Jan 2026

Frailty metabolomic signature predicts mortality in humans.

“Higher signature levels were significantly associated with increased risks of all-cause and cause-specific mortality, including cancer, cardiovascular, respiratory, and digestive deaths.”

Humans

Frailty-related plasma metabolomic signatures predict long-term mortality risk and implicate systemic aging pathways: evidence from a prospective cohort study

npj aging·13 Jan 2026